Balance In OND Offices' Staffing Drives CDER Reorganization - Jenkins
This article was originally published in The Tan Sheet
Executive Summary
The FDA Office of Nonprescription Products' capacity to be part of a larger unit was a factor in reorganizing ONP into an office that also includes medical imaging oversight, drug center executive John Jenkins says
You may also be interested in...
FDA's ONP Reorganization Challenges Industry To Prioritize OTCs
FDA says OTC drug oversight remains important even as the Office of Nonprescription Products loses star billing within the Office of New Drugs, but the change could challenge firms to convince the agency to prioritize regulation of their products
FDA OTC Head Ganley Talks Third Class, Plan B And Drug Switches
This spring, FDA's Division of OTC Drug Products will be elevated to full office status within the Center for Drug Evaluation & Research. OTC Division Director Charles Ganley, MD, sat down with "The Tan Sheet" on Dec. 17 to discuss the ramifications of the organizational change, as well as hot-button issues such as the current Rx-to-OTC switch environment, possible monograph system improvements and advisory committee reviews.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC